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A B S T R A C T
Background: Multi-target drugs have gained significant recognition for the treatment of multifactorial diseases
such as depression. Under a screening study of multi-potent medicinal plants with claimed antidepressant-like
activity, the phenolic-rich Annona muricata aqueous extract (AE) emerged as a moderate monoamine oxidase A
(hMAO-A) inhibitor and a strong hydrogen peroxide (H2O2) scavenger.
Purpose: In order to protect this extract from gastrointestinal biotransformation and to improve its permeability
across the blood-brain barrier (BBB), four phospholipid nanoformulations of liposomes and phytosomes func-
tionalized with a peptide ligand promoting BBB crossing were produced.
Methods: AE and nanoformulations were characterized by HPLC-DAD-ESI-MSn, HPLC-DAD, spectrophotometric,
fluorescence and dynamic light scattering methods. Cytotoxicity and permeability studies were carried out using
an in vitro transwell model of the BBB, composed of immortalized human microvascular endothelial cells
(hCMEC/D3), and in vitro hMAO-A inhibition and H2O2 scavenging activities were performed with all samples.
Results: The encapsulation/binding of AE was more efficient with phytosomes, while liposomes were more
stable, displaying a slower extract release over time. In general, phytosomes were less toxic than liposomes in
hCMEC/D3 cells and, when present, cholesterol improved the permeability across the cell monolayer of all tested
nanoformulations. All nanoformulations conserved the antioxidant potential of AE, while phosphatidylcholine
interfered with MAO-A inhibition assay.
Conclusions: Overall, phytosome formulations registered the best performance in terms of binding efficiency,
enzyme inhibition and scavenging activity, thus representing a promising multipotent phenolic-rich nanoshuttle
for future in vivo depression treatment.
Introduction
Major depressive disorder (MDD) is a highly prevalent multi-fac-
torial mental disorder. Since current therapies - tricyclic anti-
depressants (TCAs), selective serotonin and/or noradrenaline reuptake
inhibitors (SSRIs, NRIs, SNRIs), and monoamine oxidase-A inhibitors
(MAO-AIs) – have delayed onset of action and a substantial fraction of
patients fail to respond to them (Carvalho et al., 2017), the develop-
ment of new, fast-acting multi-targeted antidepressants with strong
efficacy is deemed urgent to increase the range of options for patients’
Abbreviations: AE, aqueous extract; ApoE, apolipoprotein E; BBB, blood-brain barrier; CNS, central nervous system; DCM, dichloromethane; DMSO, dimethylsulfoxide; DSPE-PEG-
maleimide, 1,2-stearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(-poly(ethylene glycol)-2000)]; DIV, day in vitro; EBM-2, endothelial growth basal medium; EP, endothelial
permeability; EtOAc, ethyl acetate; FBS, fetal bovine serum; FGF, fibroblast growth factor; H2O2, hydrogen peroxide; hMAO-A, monoamine oxidase A human recombinant; hCMEC/D3,
immortalized human microvascular endothelial cells; HEPES, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid; KH2PO4, potassium di-hydrogen phosphate; K2HPO4, dipotassium
hydrogen phosphate; L, liposomes without cholesterol; LC, liposomes with cholesterol; LDLr, low-density lipoprotein receptors; MAO-AI, monoamine oxidase A inhibitor; MDD, major
depressive disorder; MTT, 3-(4,5-dimetiltiazol-2-yl)-2,5-diphenyltetrazolium bromide; NRIs, noradrenaline reuptake inhibitor; P, phytosomes without cholesterol; PBS, phosphate buf-
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treatment. Thus, multi-component herbal drugs that are able to interact
with several targets involved in the pathogenesis of depression are a
promising choice (Yan et al., 2016).
The greatest obstacle in delivering a neuroactive agent to its target
is the blood–brain barrier (BBB), a physical barrier that regulates the
flow of drugs from the blood circulation to brain interstitial fluid, as
well as ensures the homeostasis of the central nervous system (CNS). Its
neurovascular unit is a complex system that encompasses endothelial
cells, astroglia, pericytes, perivascular mast cells, and all the related
interactions (Masserini, 2013). The obstruction of the paracellular
pathway through tight junctions that connect the BBB's endothelial cells
protects the brain from toxic molecules, while vital molecules are
transcellularly transported from the blood to the brain by means of
lipid-mediated free diffusion or carrier- or receptor-mediated transport
(RMT) through the BBB (Re et al., 2011; Masserini, 2013; Zhou et al.,
2014b). Among the several nanocarriers that have been designed to
increase neuroprotective drug bioavailability, liposomes and phyto-
somes have attracted increasing attention. They combine the ability to
incorporate and deliver large amounts of loaded compounds, with the
possibility of functionalizing their surface with different ligands, such
as a modified peptide derived from the receptor-binding domain of
apolipoprotein E (mApoE) (Masserini, 2013). mApoE-functionalized
nanoparticles can mimic lipoprotein particles that are endocytosed into
the BBB endothelium via low-density lipoprotein receptors (LDLr) and
can be transported across the BBB both in vitro and in vivo (Re et al.,
2011; Balducci et al., 2014; Bana et al., 2014). Functionalization with
mApoE has proved to be a successful approach to brain targeting. One
of its breakthroughs is, for example, the production of liposomes bi-
functionalized with phosphatidic acid and/or cardiolipin and with
ApoE or mApoE for in vivo reduction of amyloid beta plaques, an in-
novation described in patent US 8877236 B2 (Masserini et al., 2014).
Polar herbal compounds, such as phenolics, are strongly active in in
vitro systems but poorly absorbed in vivo due to several factors, namely
their large molecular size, degradation in the gastrointestinal tract and
poor lipid solubility, which limits their bioavailability (Bernardo et al.,
2017). In liposomes, polar plant extracts are entrapped in the water
compartment and surrounded by the phospholipid bilayer; on the
contrary, in phytosomes a complex involving chemical bonds is formed
between the polar substances and the polar heads of the phospholipid
bilayer. This dispositional difference results in a more efficient storage
of the plant extract in phytosomes than in liposomes (Ajazuddin et al.,
2010; Yu et al., 2016).
In a previous paper, we described the in vitro inhibition of an aqu-
eous extract from the leaves of Annona muricata L. over monoamine
oxidase A (MAO-A) activity (Grosso et al., 2015). Moreover, the etha-
nolic extract has recently demonstrated its antidepressant-like effect by
reducing the immobility time and increasing the swimming time in the
forced swim test using Sprague-Dawley rats (Bikomo et al., 2017). In
the current paper, in order to enhance the extract's ability to cross the
BBB, four different formulations of liposomes and phytosomes func-
tionalized with mApoE were prepared and their cytotoxicity and per-
meability were assessed using the monoculture BBB model composed of
immortalized human microvascular endothelial cells (hCMEC/D3). The
encapsulation/binding efficiency of the extract and respective release
rates for the produced formulations were assessed, as well as the con-
servation of the extract activity against MAO-A and as H2O2 scavenger
upon incorporation in the drug carriers.
Material and methods
Plant material
A. muricata leaves (lots nr. 3611.184.14, 3611.241.13, 3611.028.16,
3611.252.16) were purchased from Morais e Costa & CA. Lda (Porto,
Portugal). A. muricata fruit (lot nr.1016E16) was acquired from Fiel
Lourenço Lda (S. Julião do Tojal, Portugal). Seeds were separated from
the rest of the fruit and desiccated at 50 °C for 48 h. The plant material
was powdered to a mean particle size below 910 µm before extractions
and stored at room temperature in plastic flasks protected from light.
Reagents and standards
Cholesterol and 1,2-stearoyl-sn‑glycero‑3-phosphoethanolamine-N-
[maleimide(-poly(ethylene glycol)−2000)] (DSPE-PEG-maleimide)
were purchased from Avanti Polar Lipids (USA). L-α-phosphatidylcho-
line from egg yolk, Type XI-E was purchased from Sigma–Aldrich
(Steinheim, Germany). mApoE (CWG-LRKLRKRLLR-NH2) was pur-
chased from DBA Italia (Segrate, Italy). The hCMEC/D3 cell line was
obtained under license from Institut National de la Sante et de la
Recherche Medicale (INSERM, Paris, France).. Rat type I collagen, 1/
100 chemically defined lipid concentrated, and all the media and sup-
plements for cell culture were purchased from Gibco (Invitrogen,
Paisley, UK). Monoamine oxidase A (MAO-A, human recombinant),
kynuramine, tyramine, 4-aminoantipyrine, clorgyline, ascorbic acid, p-
coumaric acid, epicatechin, 3-(4,5-dimetiltiazol-2-yl)−2,5-diphenylte-
trazolium bromide (MTT), sepharose Cl-4B, diethyl ether, tetra-
hydrofuran, methanol, chloroform, dichloromethane and H2O2 30% wt
were purchased from Sigma-Aldrich (St. Louis, MO, USA, and
Steinheim, Germany). 5-O-Caffeoylquinic acid, quercetin-3-O-galacto-
side, quercetin-3-O-glucoside, quercetin-3-O-rutinoside, kaempferol-3-
O-rutinoside and catechin were obtained from Extrasynthèse (Genay,
France). Formic acid, acetonitrile hipersolv, methanol hipersolv,
hexane, HCl 37% and ammonium 25% were from VWR (Fontenay-sous-
Bois, France). Acetonitrile LC–MS grade and methanol LC-MS grade
were supplied by Scharlau (Barcelona, Spain). Formic acid 98% PA-ACS
was obtained from Panreac (Barcelona, Spain). Ethyl acetate and
ethanol absolute were from Carlo Erba (Val de Reuil Cedex, France).
Potassium di-hydrogen phosphate (KH2PO4) and dipotassium hydrogen
phosphate (K2HPO4) were obtained from Merck (Darmstadt, Germany)
and vanillic acid from Fluka Chemie GmbH (Buchs, Switzerland).
Extraction procedures
The aqueous extract (AE) from A. muricata leaves was prepared by
mixing 3 g of plant material with 500ml of water at 100 °C for 20min.
After filtration, the extract was lyophilized.
The seed oil was removed using stirring maceration with hexane for
3 h. Then, ethyl acetate (EtOAc) and dichloromethane (DCM) extracts
were prepared in a proportion of 1 g seeds:100ml of solvent according
to the following steps: 30min of sonication; 2 h of stirring maceration
(200 rpm) at room temperature; 30min of sonication. Afterwards, the
organic extracts were filtrated, and the solvent evaporated under re-
duced pressure. The obtained extraction yields were: 18.0 ± 2.0%
(leaves, AE), 3.8 ± 0.4% (seeds, EtOAc) and 3.2 ± 0.5% (seeds,
DCM).
HPLC-DAD-ESI-MSn analyses
Samples were injected on an HPLC Accela (Thermo Fischer
Scientific, Bremen, Germany) using a C18 Spherisorb ODS2
(25.0×0.46 cm; 5 µm particle size) column from Waters (Ireland).
Phenolic compounds and alkaloids were analyzed in the negative and
positive ion modes, respectively. The solvent system consisted in formic
acid 1% (A) and methanol (B), starting with 5% B. The gradient in-
stalled was according to Grosso et al., (2015) with a solvent flow rate of
0.92ml/min. Acetogenins were analyzed in the positive ion mode ac-
cording to the gradient proposed by Le Ven et al. (2014): 40% B at
0 min, 100% B at 25 min, and held for 15 min at 100% B. Two eluent
systems were tested, water (A) and acetonitrile (B) and formic acid 1%
(A) and acetonitrile (B), the last one giving higher intensities in MS.
Chromatograms were recorded at 220, 280, 320 and 350 nm in order to
explore the presence of acetogenins, alkaloids and phenolic compounds.
Analyses were performed on an LTQ Orbitrap™ XL hybrid mass
spectrometer (Thermo Fischer Scientific, Bremen, Germany) controlled
by LTQ Tune Plus 2.5.5 and Xcalibur 2.1.0, in negative and positive
mode. The capillary voltage of the electrospray ionization source (ESI)
was set to 3.0 kV (negative mode) and 3.1 kV (positive mode). The
capillary temperature was 275 °C. The sheath gas and auxiliary gas flow
rate were at 40 and 10 (arbitrary unit as provided by the software
settings). The capillary voltage was −35 V (negative mode) or 48 V
(positive mode) and the tube lens voltage −200 V for negative mode
and 120 V for positive mode.
MS data handling software (Xcalibur QualBrowser software,
Thermo Fischer Scientific) was used to search for predicted metabolites
by their m/z value. All peaks were check for m/z value and fragmen-
tation products.
Compounds were identified by comparing their retention times, MS
and UV–vis spectra with pure standards and data from literature.
HPLC-DAD analyses
AE was analyzed on an analytical HPLC unit (Shimadzu) as pre-
viously described (Moreira et al., 2017) using the same gradient sys-
tems as for HPLC-DAD-ESI-MSn analyses. The eluent systems consisted
in formic acid 5% (A) and methanol (B) (for phenolic compounds and
alkaloids) or water (A) and acetonitrile (B) (for acetogenins).
The quantification of phenolic compounds was achieved using ex-
ternal calibration curves obtained at 280 nm (for flavan-3-ols and
procyanidins), 320 nm (for hydroxycinnamic acids) and 350 nm (for
flavonols) (Supplementary data, section S1, Table S1). Compounds 1–3,
5 and 7 were quantified as catechin, compound 4 as 5-O-caffeoylquinic
acid, compound 6 as epicatechin, compound 8 as p-coumaric acid,
compound 13 as quercetin-3-O-galactoside, compounds 14 and 17 as
quercetin-3-O-glucoside, compounds 9–12, 15, 16, 20 and 21 as quer-
cetin-3-O-rutinoside, and compounds 18+ 11 and 22 as kaempferol-3-
O-rutinoside.
Liposomes preparation
Liposomes with two different compositions were prepared. One, by
mixing L-α-phosphatidylcholine/cholesterol/DSPE-PEG-maleimide
(65:32.5:2.5, M:M:M), and the other, composed by 97.5 mol% L-α-
phosphatidylcholine and 2.5 mol% DSPE-PEG-maleimide. Lipids were
dissolved in chloroform. The solvent was evaporated under reduced
pressure and the lipid films were stored overnight in the freezer. Lipid
films were hydrated with 100 µL of borate buffer (pH 10). Four mg of
the AE dissolved in 150 µL of the same buffer were added to each lipid
film. After 3 cycles of sequential vortexing and sonication (1min each),
5 cycles of freezing (dry ice, 5 min) - thawing (65 °C, 5min) and so-
nication (5min) were performed. Subsequently, the volume was ad-
justed to 1ml with PBS and submitted to 15min of additional sonica-
tion. Liposomes were gel filtered on a sepharose Cl-4B column, eluted
with PBS, and the fractions containing the liposomes were collected.
Further surface functionalization with mApoE peptide was carried out
for BBB targeting. mApoE peptide, carrying the amino acid sequence
CWG-LRKLRKRLLR and containing residues 141–150 of the receptor-
binding protein of human ApoE, was reacted at room temperature
overnight to form a covalent thioether bond with DSPE-PEG-maleimide,
resulting in formation of liposomes functionalized with 1.25 mol%
mApoE. Two nanocarriers were produced by adopting this procedure:
liposomes with and without cholesterol incorporating the AE (mApoE-
LC-AE and mApoE-L-AE, respectively). Non-functionalized nanocarriers
(LC-AE and L-AE) were also produced for the transwell assay.
Phytosomes preparation
Three ml of tetrahydrofuran were added to a mixture containing 4:1
of phosphatidylcholine and plant extract and the reaction was stirred at
75 °C for 4 h to achieve maximum yield of extract binding. After drying
under reduced pressure, the mixture was diluted in chloroform and
filtered through 0.45 µm PTFE membranes to remove the unbound
extract. The extract-phospholipid complex was further modified by
adding 32.5 mol% cholesterol and 2.5 mol% DSPE-PEG-maleimide or
just 2.5 mol% DSPE-PEG-maleimide. The lipid film was rehydrated with
PBS and submitted to three cycles of vortexing/sonication (1+ 1min)
and additional sonication for 15min. Following the latter procedure,
both types of phytosomes were functionalized with 1.25% of mApoE by
overnight incubation. Two phytosome formulations were produced
using this methodology: phytosomes with and without cholesterol
complexed with the AE (mApoE-PC-AE and mApoE-P-AE, respectively).
Non-functionalized phytosomes (PC-AE and P-AE) were also produced
for the transwell assay.
Characterization of liposomes and phytosomes
The size and polydispersity index (PDI) of diluted mApoE-L-AE,
mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE were measured at 25 °C
by dynamic light scattering (DLS) with a Z90-Plus device (Brookhaven
Instruments Corporation, Holtsville, NY, U.S.A.). The amount of phos-
phatidylcholine/cholesterol was quantified by the Stewart's method
(ammonium ferrothiocyanate) at 485 nm (Stewart, 1980).
In order to determine the amount of AE incorporated within the
liposomes and phytosomes, an aliquot of the nanoformulation solution
was withdrawn after decoration with mApoE, processed with 2:1
chloroform: methanol so as to disrupt the drug carrier and quantified by
measuring the absorbance at 272 nm with a Jasco 530 spectro-
photometer, since the extract presents the main absorption maximum at
this wavelength. Empty nanocarriers processed with 2:1 chloroform:
methanol were used as the baseline. Moreover, each nanoformulation
was submitted to HPLC-DAD analysis, using the same procedures
adopted for the extracts.
As an independent assessment of the quantity of AE, the intensity of
the fluorescence emitted at 469 nm by the same solution upon excita-
tion at 393 nm was also measured with a Cary Eclipse spectro-
fluorimeter and compared to a calibration curve obtained for the ex-
tract dissolved in milliQ water (see Supplementary data, section S3, Fig.
S3).
The leakage over time was assessed by means of the same methods,
keeping the formulations under dialysis for as long as 4 days and
withdrawing sample aliquots for separation and quantification of the
extract at different times.
The maintenance of pH=10 within the mApoE-L-AE and mApoE-
LC-AE was assessed over time by fluorescence spectroscopy as detailed
in the Supplementary data.
Cell cultures
hCMEC/D3 cells were used as a representative human BBB model.
They were cultured at 37 °C, 5% CO2/saturated humidity in EBM-2
medium supplemented with 5% FBS, 1% pen–strep, 1.4 µM hydro-
cortisone, 5 µg/ml ascorbic acid, 1/100 chemically defined lipid con-
centrate, 10mM HEPES and 1 ng/ml basic FGF (Bana et al., 2014;
Mancini et al., 2016). For the MTT assays, cells (passage 25–35) were
seeded in a collagen coated 96 well-plate at a density of 10,000 cells/
well.
MTT assay
Cells were treated with different doses of AE, mApoE-L-AE, mApoE-
LC-AE, mApoE-P-AE and mApoE-PC-AE for 3 h and the cell viability
was then evaluated by means of the MTT assay (Re et al., 2011). MTT
was dissolved in PBS (0.5% w/v), added to the cells and incubated for
2 h at 37 °C in a humidified chamber. After incubation, ethanol was
added to each well to dissolve the formazan crystals formed.
Absorbance at 550 nm was measured using a microplate reader (Victor3
1420 Multilabel Counter, Perkin Elmer, Boston, MA, USA). Untreated
cells were used as a negative control.
Transwell assay
In order to set up the BBB model for permeability experiments,
hCMEC/D3 cells (passage 25 - 35) were cultured on 12-well transwell
inserts coated with type I collagen in a density of 5×104 cells/cm2.
The layer of endothelial cells separates this system into an apical ‘blood’
side (0.5 ml of volume) and a basolateral ‘brain’ side (1ml of volume)
compartment. Bioelectrical properties of the cell monolayer were
checked by measuring the transendothelial electrical resistance (TEER)
with STX2 electrode Epithelial Volt-Ohm meter (World Precision
Instruments, Sarasota, Florida). Morphological and functional proper-
ties of the cell monolayer were evaluated by examining cells under
microscope, as well as by measuring the paracellular permeability of
250 µM FITC-dextran (MW 4 kDa) and the transcellular permeability of
76 nM [3H]-propranolol (0.5 µCi), as previously described (Bana et al.,
2014). Cell viability was also assessed by MTT assay (Orlando et al.,
2013).
The cellular transport of AE, mApoE-L-AE, mApoE-LC-AE, mApoE-
P-AE and mApoE-PC-AE was estimated by placing 0.5 ml of samples
(100 µg/ml of AE) suspension in PBS on the upper chamber followed by
incubation at 37°C for 3 h. The endothelial permeability (EP) of AE,
mApoE-L-AE, mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE across
the cell monolayers was estimated by measuring the absorbance of the
AE at different times (up to 3 h) in the upper and lower chambers by
means of a spectrophotometer (wavelength= 272 nm), and calculated
as described before (Cecchelli et al., 1999). Nanocarriers without
mApoE were also tested (L-AE, LC-AE, P-AE and PC-AE).
MAO-A inhibition assays
The inhibition of MAO-A activity was evaluated using two methods.
One of them was based on the horseradish peroxidase-linked assay
described by Holt et al. (Holt et al., 1997), with the modifications
proposed in subsequent papers (Stafford et al., 2007; Grosso et al.,
2013). The reaction was monitored for 20min at 490 nm in a micro-
plate reader Biotek Synergy HT (Winooski, Vermont, USA). The other
method was based on the production of 4-hydroxyquinoline from the
deamination of kynuramine (Weissbach et al., 1960) and it was applied,
with minor modifications, by adopting the procedure described in en-
suing papers (Dittmann et al., 2004; Novaroli et al., 2005). When em-
ploying this method, 5 µl of AE and nanoformulations (mApoE-L-AE,
mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE) were mixed with
350 µl of potassium phosphate buffer (0.1M, pH 7.4) and 20 µl of ky-
nuramine (3.75mM) and the reaction was initiated with 125 µl of
MAO-A (17 U/ml). The production of 4-hydroxyquinoline was de-
termined by measuring the absorbance at 314 nm with a Shimadzu UV-
260 spectrophotometer (Kyoto, Japan), after incubation at 37 °C for
70min. For each tested concentration, a blank sample (without MAO-A)
was used for background subtraction. mApoE-P-AE and mApoE-PC-AE
were dissolved in a mixture of buffer with DMSO and, in both methods,
a concentration of DMSO below 6% did not affect the enzyme activity.
The IC50 values were calculated by performing three independent as-
says in triplicate and comparing them with the ones obtained for
clorgyline (positive control).
Hydrogen peroxide scavenging activity
The adopted procedure to evaluate the AE's scavenging ability
against H2O2 was based on the disappearance of the H2O2 signal at
230 nm (Gülçin et al., 2006). In each tube, 425 µl of AE or mApoE-L-AE,
mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE dissolved in 0.1 M
phosphate buffer (pH 7.4) (or merely buffer for the negative control)
were mixed with 75 µl of 40 mM solution of H 2O2. The absorbance
value at 230 nm was read after 10min of incubation by means of a
Shimadzu UV-260 spectrophotometer (Kyoto, Japan). For each tested
dilution, a blank sample (without H2O2 solution) was used for back-
ground subtraction. Ascorbic acid was used as reference for all assays.
Three independent assays were performed in triplicate.
Statistical analysis
All data were recorded as mean ± SD or mean ± SEM. The IC50
values were calculated using Graph Pad Prism Software Version 6. For
the viability and permeability tests, samples were compared and
grouped according to one-way analysis of variance (ANOVA), using
Bonferroni as post-test (Graph Pad Prism Software Version 6).
Differences at p<0.05 were considered statistically significant.
Results and discussion
HPLC-DAD-ESI-MSn and HPLC-DAD analyses
Several phenolic compounds were detected in the aqueous extract of
A. muricata. Compounds 1, 3 and 4 showed deprotonated molecular
ions characteristic of caffeoylquinic acids ([M-H]− at m/z 353). Base
peaks at m/z 191 [quinic acid-H]− (compounds 1 and 4) and at 173
[(quinic acid-H)−18]− (compound 3) were obtained from MS2 [353]
fragmentation. Taking into consideration their Rt and their fragmen-
tation pattern (Clifford et al., 2003), these compounds can be assigned
as 3-O-caffeoylquinic acid (1), 4-O-caffeoylquinic acid (3), and 5-O-
caffeoylquinic acid (4). All these compounds were previously described
in A. muricata (Marques et al., 2009; Nawwar et al., 2012). The UV
spectra of peaks 1 and 3 denote co-elution with other class of com-
pounds, which was confirmed by MS spectra. Therefore, a fragmenta-
tion pattern characteristic of procyanidin derivatives was observed,
with a deprotonated molecular ion at m/z 577 being fragmented into
characteristic ions at m/z 425 (base peak, retro-Diels-Alder(RDA)
cleavage), 407 [425–18]−, and 289 [catechin-H]− in the MS2 spectrum
(Rockenbach et al., 2012; Ferraz et al., 2017). This fragmentation
pattern was also observed for compound 7 (Table 1, Fig. 1A). In fact,
procyanidins and procyanidin derivatives were already identified in
different species of Annona genus, such as A. crassiflora (Ferraz et al.,
2017; Justino et al., 2017) and A. cherimola (Santos et al., 2016).
Compounds 2 and 6 present similar UV and MS spectra ([M-H]− at
m/z 289) and their identification was confirmed with pure standards of
catechin (2) and epicatechin (6). Both compounds showed character-
istic MS2 fragments at m/z 245 (base peak, [(M-H)-CO2]−) and 205
(cleavage of the A-ring of the flavan-3-ol) (Rockenbach et al., 2012;
Ferraz et al., 2017) (Table 1, Fig. 1A). Nawwar et al., (2012) and
(George et al., 2015) have already reported the presence of these
flavan-3-ol in hydroalcoholic and aqueous extracts of A. muricata. MS
fragmentation of compound 5 showed not only a caffeic acid derivative
but also a catechin derivative. The MS2 fragmentation of the ion at m/z
179 yielded a base peak at m/z 135 which corresponded to [(caffeic
acid-H)-CO2]−. However, in the MS spectrum is also observed an ion at
m/z 353 (which may be a precursor of m/z 179), indicating that the
peak does not correspond to caffeic acid but to a caffeic acid derivative.
Moreover, this peak also contains a catechin derivative since a base
peak at m/z 289 [catechin-H]− is observed in the MS2 fragmentation of
the ion at m/z 469 (Table 1, Fig. 1A).
The chromatographic behavior of compound 8, as well as its UV and
MS spectra (Rt 26.03min; UV 309 nm; [M-H]− at m/z 163, MS2[163]:
119 (100%)) was coincident with those of p-coumaric acid standard
(Ferreres et al., 2013), a compound already reported in this species
(George et al., 2015).
Compounds 9–17 and 19–21 correspond to glycosylated quercetin
derivatives. The assignment of compounds 13 and 14 was confirmed by
injection of pure standards of quercetin-3-O-galactoside (13) and
quercetin-3-O-glucoside (14) ([M-H]− at m/z 463 and a base peak at m/
z 301 in MS2, corresponding to the loss of the hexosyl radical, = 162
amu) (Table 1, Fig. 1A) (Nawwar et al., 2012). With a deprotonated
molecular ion 30 amu less than those of compounds 13 and 14 and a
base peak at m/z 300 in MS2[433], compound 17 is a quercetin-3-O-
pentoside, probably quercetin-3-O-arabinoside (Table 1, Fig. 1A) al-
ready found in A. crassiflora (Lage et al., 2014). MS spectra of com-
pound 9 presented a deprotonated molecular ion at m/z 741, which
produced fragments at m/z 579 (−162 amu, hexosyl radical), 462/463
(−278 amu, rhamnosyl-pentosyl radical) and 299/300 (−441 amu,
hexosyl-rhamnosyl-pentoside-H radical). Since ions resulting from the
loss of the sugar moieties are more intense than that of the aglycone in
MS2, sugar molecules are probably linked to different phenolic hydroxyl
groups (Amaral et al., 2005; Ferreres et al., 2008). In the MS3 [741], a
base peak at m/z 300 [aglycone-2H]− was observed (Amaral et al.,
2005). Therefore, compound 9 can be tentatively labelled as quercetin-
hexoside-rhamnosyl-pentoside (Table 1, Fig. 1A). Compounds 10 and
11 possess the same MS fragmentation pattern, with a deprotonated
molecular ion at m/z 625. The MS2[625] fragmentation yielded frag-
ments at m/z 505 [M-H-120]−, 463[M-H-162]− (loss of hexosyl ra-
dical), 445[M-H-162-18]− (loss of hexosyl and water), and a base peak
at 300 [aglycone-2H]−. Thus, both compounds correspond to quer-
cetin-di-O-hexosides (Table 1, Fig. 1A). Compound 12 can be tenta-
tively identified as rutin-O-pentoside since in the MS fragmentation a
deprotonated molecular ion at m/z 741 is observed. In the MS2 frag-
mentation, ions at m/z 609[M-H-pentosyl]− and a base peak at m/z
300, which correspond to quercetin aglycone, were produced (Table 1,
Fig. 1A) (Ferraz et al., 2017). Compounds 15 and 16 are isomers. These
two compounds possess the same deprotonated molecular ion (m/z at
609) and a base peak corresponding to 301/300[aglycone-H/2H]− was
observed in the MS2[M-H]− fragmentation. Therefore, compound 15 is
quercetin-3-O-rhamnosyl-(1→6)-glucoside (quercetin-3-O-rutinoside)
which was confirmed by injection of the pure standard and compound
16 is an isomer and can tentatively be assigned as quercetin-3-O-
rhamnosyl-(1→6)-galactoside (=quercetin-3-O-robinobioside). In
both, 0,2X0−at m/z 343 was observed, confirming 1→6 interglycosidic
linkage (Cuyckens et al., 2001) (Table 1, Fig. 1A). Indeed, these two
compounds were already identified in this species (Matsushige et al.,
2012b; Nawwar et al., 2012). In the MS fragmentation of compound 20
and 21, besides their [M-H]− at m/z 609 and m/z 579, an ion at m/z
447 was observed, corresponding to the loss of an hexosyl radical [(M-
H)−162]− and pentosyl radical [(M-H)−132]−, respectively. There-
fore, these compounds can be tentatively identified as quercetin-hex-
osyl-rhamnoside (20) and quercetin-pentosyl-rhamnoside (21). Since
[Aglycone-H/2H]− is the base peak in both MS2 spectra, both sugars
are linked to the same phenolic carbon of the quercetin aglycone
(Amaral et al., 2005; Ferreres et al., 2008) (Table 1, Fig. 1A). Peak 19
showed a fragmentation pattern characteristic of quercetin as well as
kaempferol derivatives, showing a co-elution of two compounds. The
MS2 fragmentation of the deprotonated molecular ion at m/z 609 ori-
ginated ions at m/z 463 [(M-H)−146]−, 429 [(M-H)−-(162+18)]−
and 300 [Aglycone-2H]− as base peak. Additionally, MS2 [593] yielded
an ion at m/z 447 [(M-H)−146]− and a base peak at m/z 285. Thus,
peak 19 contains a quercetin-rhamnosyl-hexoside and a kaempferol-
rhamnosyl-hexoside (Table 1, Fig. 1A). In both compounds, a 1→6 in-
terglycosidic linkage was confirmed by the presence of the ions at m/z
343 (for the quercetin derivative) and 327 (for the kaempferol deri-
vative) (Cuyckens et al., 2001). Other glycosylated kaempferol deri-
vatives were also detected. Compound 18 showed a [M-H]− at m/z 447
and a MS2[447] fragmentation yielding a fragment 162 amu lower (m/z
284[aglycone-2H]−). This type of fragmentation indicates that this
compound is a kaempferol-O-hexoside (Table 1, Fig. 1A); however, by
comparison with pure standard, the compound is not kaempferol-3-O-
glucoside. Finally, compound 22 was characterized by an MS frag-
mentation characteristic of kaempferol-3-O-rutinoside, already de-
scribed in this species by Nawwar et al., (2012) and Matsushige et al.,
(2012b): [M-H]− at m/z 593, another characteristic ion at m/z 447
(=146 amu, rhamnosyl radical) and, in the MS2[593], a base peak at
m/z 285 [kaempferol-H]− (Table 1, Fig. 1A). Compound's identity was
also confirmed by comparison with a pure standard. The phenolic
compounds identified accounted for 56.43mg/g of dry extract
(Table 1).
According to Matsushige et al., (2012a) and Leboeuf et al., (1981),
leaves are also a source of alkaloids such as annonamine, anonaine,
Table 1
Phenolic composition of the aqueous extract from A. muricata leaves. Results are expressed as mean ± SD of three analyses.
Compound Rt (min) UV (nm) [M-H]−, m/z MS2[M-H]−, m/z (%) Amount (mg/g extract, d.w.)
1 3-O-Caffeoylquinic acid + procyanidin derivative 10.21 287, 325 353.08833 191(100), 179(48) 2.16 ± 0.05
577.13576 425(100), 407(81), 289(25)
2 Catechin 13.80 279 289.07188 245(100), 205(35) 1.93 ± 0.03
3 4-O-Caffeoylquinic acid + procyanidin derivative 16.05 283, 326 353.08842 173(100), 179(60) 4.64 ± 0.02
577.13667 425(100), 407(67), 289(22)
4 5-O-Caffeoylquinic acid 17.37 248, 293sh, 326 353.08888 191(100), 179(4) 4.14 ± 0.04
5 Caffeic acid derivative+ catechin derivative 18.53 286, 323 179.03537 135(100) 4.70 ± 0.55
469.11460 289(100)
6 Epicatechin 19.85 279 289.07230 245(100), 205(34), 179(13) 6.23 ± 0.01
7 Procyanidin derivative 22.40 283, 308sh 577.13574 425(100), 407(19), 289(17) 3.52 ± 0.50
8 p-Coumaric acid 26.03 309 163.04045 119 (100) 2.45 ± 0.52
9 Quercetin-hexoside-rhamnosyl-pentoside 31.19 265, 345 741.18909 579(100), 462(22), 300(5) 0.79 ± 0.00
10 Quercetin di-O-hexoside 35.18 259, 267, 349 625.14197 301(61), 300(100) 0.90 ± 0.00
11 Quercetin di-O-hexoside 35.86 265, 347 625.14210 301(37), 300(100) 0.86 ± 0.01
12 Rutin-O-pentoside 41.04 257, 267, 354 741.18977 609(40), 301(49), 300(100) 4.11 ± 0.01
13 Quercetin-3-O-galactoside 43.04 256, 267, 356 463.09034 301(100) 2.71 ± 0.02
14 Quercetin-3-O-glucoside 43.40 257, 267, 355 463.08977 301(100) 1.71 ± 0.02
15 Quercetin-3-O-rutinoside 43.85 256, 267, 355 609.14818 301(100) 5.11 ± 0.01
16 Quercetin-3-O-robinobioside 44.34 257, 350 609.14658 301(100) 0.39 ± 0.01
17 Quercetin-3-O-pentoside 45.09 258, 267, 354 433.07868 301(75), 300(100) 1.43 ± 0.01
18 Kaempferol-3-O-hexoside 46.11 266, 340 447.09401 285(57), 284(100) 0.72 ± 0.03 (18+ 19)
19 Quercetin-rhamnosyl-hexoside+Kaempferol-rhamnosyl-
hexoside
46.43 266, 340 609.14664 301(37), 300(100)
593.15149 285(100)
20 Quercetin-hexosyl-rhamnoside 46.76 258, 267, 348 609.14680 301(29), 300(100) 2.10 ± 0.02
21 Quercetin-pentosyl-rhamnoside 47.06 256, 266, 348 579.13807 301(14), 300(100) 5.33 ± 0.05
22 Kaempferol-3-O-rutinoside 47.68 265, 347 593.15131 285(100) 0.50 ± 0.00
Total 56.43 ± 1.36
Fig. 1. HPLC-DAD chromatogram of A. muricata. (A) Detection at 350 nm of the aqueous extract (AE) from the leaves (negative ion mode); (B) Detection at 280 nm of
the AE from the leaves (positive ion mode); (C) Detection at 220 nm of the dichloromethane extract (DCM) from the seeds (positive mode); (D) Detection at 220 nm of
the AE from the leaves (positive ion mode). Identity of the compounds as in Table 1 and as described in “HPLC-DAD-ESI-MSn and HPLC-DAD analyses” section.
O,O-dimethylcoclaurine, 4′-O-methylcoclaurine, (+)-norcorydine, co-
claurine, reticuline and stepharine. Based on MS spectra, only trace
amounts of coclaurine (23, Rt: 24.37min; [M+H]+, m/z: 286;
MS2[M+H]+ m/z (%): 269(100), 178(1), 175(5), 151(3), 137(3),
107(4)) and of reticuline (24, Rt: 34.14min; [M+H]+, m/z: 330;
MS2[M+H]+ m/z (%): 299(5), 192(100), 175(1), 137(1)) were de-
tected (Stévigny et al., 2004; Schmidt et al., 2005; Rottscholl et al.,
2016) (Fig. 1B, supplementary data, section S2, Fig. S1). The absence of
almost all previously reported alkaloids may be related with the ex-
traction procedure employed in the current study. Indeed,
Matsushige et al., (2012a) extracted the alkaloid fraction with MeOH
followed by partitioning with n-hexane, chloroform, ethyl acetate and
buthanol successively.
Acetogenins are usually regarded as lipophilic neurotoxins
(Caparros-Lefebvre et al., 1999; Champy et al., 2005). In order to assess
the presence or absence of acetogenins in the aqueous extract, an or-
ganic extract (DCM) prepared from the seeds, a rich source of this class
of compounds, was used for comparative purposes. Acetogenins possess
UV spectra with a maximum at 210–220 nm and produce characteristic
ion patterns consisting of [M+Na]+ and [M+H]+ molecular ions, as
well as ions corresponding to consecutive losses of H2O (−18 amu)
from the [M+H]+ ion (Alali et al., 1999). Therefore, the mass spec-
trum of peaks 25–30, 33, 34 and 38 in the DCM extract from the seeds
(Fig. 1C) presented as major ion peak at m/z 613, corresponding to the
[M+H]+, and the fragmentation of that pseudomolecular ion yielded
5 consecutive losses of H2O (m/z 595, 577, 559, 541, 523 and 505) as
shown in Fig. S2 (supplementary data, section S2). The mass spectrum
of peaks 31, 32, 35–37, 39–41 showed a major ion peak at m/z 597
and, once again, 5 consecutive losses of H2O, yielding the ions at m/z
579, 591, 543, 525 and 507 (Fig. S2, supplementary data, section S2).
Some acetogenins with molecular mass of 612 and 596 g/mol are de-
scribed in the literature (Alali et al., 1999). Regarding the AE, as it can
be seen in the chromatogram (Fig. 1D), and analysing the UV and MS
spectra, we concluded that acetogenins where not detected in this ex-
tract, which suggests reduced side effects for pharmaceutical formula-
tions derived from this source. According to some authors (Caparros-
Lefebvre et al., 1999; Champy et al., 2005), over-consumption of A.
muricata may have caused an atypical Parkinsonism on the islands of
Guadeloupe and Guam due to the presence of acetogenins. On the other
hand, Lannuzel et al., (2007) observed that nearly 50% of the atypical
Fig. 2. HPLC-DAD chromatogram of phytosomes with cholesterol (PC-AE) (A) and liposomes with cholesterol (LC-AE) (B, C). Detection at 350 nm (A and C) and
320 nm (B).
parkinsonism patients were not heavy consumers of annonaceaous
products while some control patients consumed them in large amounts,
which indicates that environmental or genetic factors might be also
involved. Champy et al., (2005) demonstrated that a dose of 106mg/kg
of annonacin, when infused intravenously, induced neurodegeneration
in rats, and that a daily consumption of A. muricata pulp, nectar, leaf
infusion, or leaf decoction corresponds to the ingestion of 78, 188, 0.73
and 0.73mg/kg of annonacin per year, respectively. These results
showed that aqueous extraction from the leaves does not allow to ob-
tain high amounts of these class of lipophilic compounds and, in fact,
our extraction method did not permit to detect acetogenins by HPLC-
DAD-ESI-MSn. To further reinforce the safety of polar extracts from A.
muricata leaves, Bikomo et al., (2017) and N'Gouemo et al., (1997)
reported that the ethanolic extract displayed antidepressant-like effects
on rats at 50, 150 and 300mg/kg and suppressed the tonic phase of
pentylenetetrazol (PTZ)-induced clonic-tonic seizures in mice at
5–100mg/kg, respectively. Moreover, Florence et al., (2014) observed
the antidiabetic effect of the AE on streptozotocin-induced diabetic rats
at 100 mg/kg or 200 mg/kg. In conclusion, we were able to demon-
strate that the decoction prepared in this study is rich in phenolic
compounds, two alkaloids were in trace amounts and no acetogenins
were detected.
Characterization of the extract binding efficiency and release by
nanoformulations
Phytosomes
mApoE-PC-AE and mApoE-P-AE had a mean particle size of
106 ± 9 nm and 161 ± 12 nm, respectively. Both systems were
moderately polydispersed, registering PDI values of 0.245 and 0.275,
respectively, owing to the fact that the customary extrusion procedure
was avoided to minimize extract losses. The phosphatidylcholine-ex-
tract binding efficiency was 49 ± 3%. The HPLC-DAD profile confirms
that both pharmacologically active components of the AE (i.e. phenolic
acids and flavonoids) were efficiently incorporated, enabling the
identification of the corresponding peaks (Fig. 2A). The binding reac-
tion was monitored in real time by means of fluorescence spectroscopy,
and presenting a two-step kinetics, with rapid formation of a loosely
bound AE-phosphatidylcholine transient complex followed by a slower,
more stable and permanent complexation. The details of these experi-
ments are reported in Supplementary data (see Section S4, Figs. S4 and
S5).
In regard to the release of the entrapped AE, while as much as
15 ± 3% of the AE was detached from the mApoE-P-AE within the first
30 min, only 28 ± 3% was released after 24 h. For mApoE-PC-AE,
16 ± 3% and 39 ± 2% of the AE were released after 30min and 24 h,
respectively. Although it is established that the incorporation of cho-
lesterol between the phospholipid bilayer confers stability to the na-
noformulation and retards drug release, this is not the case for hydro-
philic drugs, such as the AE of A. muricata. In fact, cholesterol cannot
protect from leakage since part of the AE is linked to the external polar
heads of phospholipids, rather than entrapped inside an inner space as
it happens with liposomes (Briuglia et al., 2015). The rapid initial
leakage (15–16%) followed by a substantial deceleration of the drug
loss is more peculiar, however, and deserving of an explanation. It
might be interpreted in the light of the reaction kinetics. In other words,
it is conceivable that, after the four h incubation of the AE with phos-
phatidylcholine in THF at high temperature, part of the extract is still
bound to the phospholipid only by means of the readily formed but
weak H-bonding pattern. This fraction of drug is easily released as soon
as the phytosomes are resuspended in H-bonding solvent (water).
Conversely, the fraction of AE that has completed the binding reaction
and is linked to phosphatidylcholine through the slowly-forming per-
manent H-bonding pattern, takes a comparably longer time to be de-
tached from the carrier.
Liposomes
mApoE-LC-AE and mApoE-L-AE had a mean particle size of
138 ± 29 nm and 195 ± 33 nm, with a PDI of 0.193 and 0.261, re-
spectively. The entrapment efficiency of the AE demonstrated by
UV–Vis absorption was 26 ± 16% (mApoE-LC-AE) and 27 ± 7%
(mApoE-L-AE). As presented in Fig. 2B and 2C, HPLC analysis indicated
that both flavonoids and phenolic acids were also efficiently in-
corporated in the case of liposomes.
After 30min, 8 ± 1% (mApoE-L-AE) and 7 ± 2% (mApoE-LC-AE)
of the AE had been released from the liposomes and after a 24-h period,
the obtained values were 21 ± 2% (mApoE-L-AE) and 22 ± 2%
(mApoE-LC-AE). The same results were independently confirmed by
fluorescence experiments. In this case, the presence of cholesterol
seemed to have a minor effect on drug leakage.
In order to verify whether the leakage was influenced by the al-
teration of the liposome's internal pH, we performed fluorescence
measurements as detailed in the Supplementary data (see
Supplementary data, Section S5, Fig. S6 and S7). The results suggest
that the internal pH remained≥ 10 over 2 days.
Viability of hCMEC/D3 and permeability of nanoformulations across a
cellular BBB model
To investigate the ability of the AE, mApoE-L-AE, mApoE-LC-AE,
mApoE-P-AE and mApoE-PC-AE to cross the BBB, we assembled an in
vitro BBB transwell model composed by a monolayer of polarized en-
dothelial cells seeded on a porous membrane, allowing an apical
compartment (‘blood’ side) to be physically separated from a baso-
lateral one (‘brain’ side). hCMEC/D3 cells were used as representative
of the human BBB model and the transwell system was characterized by
measuring its bioelectrical and functional properties. In particular, the
trans-electrical endothelial resistance (TEER) was monitored during the
cell monolayer's formation, presenting a gradual increase from
19.7 ± 2.3 Ω cm2 at 1 day in vitro (DIV) to 53.8 ± 3.5 Ω∙cm2 at 15
DIV. Moreover, at 15 DIV, the endothelial permeability (EP) values for
[3H]-propranolol and FITC-dextran (MW 4000 Da) were in the order of
2.3 ± 0.1×10–3 cm/min and 1.02 ± 0.04×10–6 cm/min, respec-
tively, which was in agreement with the values reported in the litera-
ture, showing preferentially the transcellular transport (Omidi et al.,
2003; Bicker et al., 2014).
Before performing the passage experiments across the in vitro model
of the BBB, the possible cytotoxicity of the AE, mApoE-L-AE, mApoE-
LC-AE, mApoE-P-AE and mApoE-PC-AE on hCMEC/D3 was assessed by
MTT, since the permeability of the hCMEC/D3 monolayer substantially
depends on the cells integrity. Hence, each of the above formulations
was tested at three extract concentrations: 30, 60 and 100 µg/ml, after
3 h of incubation. As depicted in Fig. 3, the AE exhibits substantial
cytotoxicity resulting in less than 60% viability even at the lowest drug
concentration. However, encapsulation in either of the carriers de-
monstrated beneficial effects on cells health, raising the viability to over
80%, even in the less favorable cases (100 µg/ml). At the lower tested
concentration, which is nonetheless already pharmacologically relevant
(vide infra), nearly 100% of viability was recorded for both carriers.
The transport of hCMEC/D3 cells was tested at 100 µg/ml of extract
concentration, entrapped or not within the nanoformulations, in order
to facilitate the spectrophotometric detection of the AE's fraction
transported across the monolayer. Although the AE was able to cross
the in vitro BBB, which may have also resulted from interference with
cell integrity (since the extract alone is substantially cytotoxic), the
permeability increased between 4 to 9-fold with nanoformulations
functionalized with mApoE (mApoE-L-AE, mApoE-LC-AE, mApoE-P-AE
and mApoE-PC-AE). This indicates that the transcellular permeability of
nanocarriers does not derive from cell unviability but from increased
transport caused by functionalization with mApoE. In particular,
mApoE-LC-AE and mApoE-PC-AE were nearly twice more effective in
facilitating the extract transport than mApoE-L-AE and mApoE-P-AE.
This outcome may possibly be related to the stability provided by
cholesterol, which allows the nanoformulations to maintain a certain
shape, thus enabling a better fusion with the BBB. Contrarily, without
cholesterol, nanoformulations are more likely to break, crossing in less
amount the BBB. Therefore, cholesterol should be included among the
constituents of an optimized brain-targeted lipid-based nanocarrier.
Nonetheless, the least cytotoxic nanoformulation was mApoE-P-AE
(≈90% cell viability). Moreover, by comparing the permeation of
mApoE-L-AE, mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE with
those nanoformulations not functionalized with this peptide (L-AE, LC-
AE, P-AE and PC-AE), it became evident that this decoration plays a
pivotal role in favoring the crossing of the BBB by nanoparticles
(Fig. 4). Such result is already well established in the literature by
several of our group's works concerning liposomes (Gobbi et al., 2010;
Re et al., 2011; Bana et al., 2014) and polymeric nanocarriers
(Gregori et al., 2015) as well as by other authors (Neves et al., 2016).
Owing to the functionalization with mApoE peptide, transporter-
mediated transport (namely receptor-mediated transcytosis) dominates
for the nanoformulations (Re et al., 2011; Bana et al., 2014).
In vitro assessments of the extract and nanoformulations biological activities
MAO-A inhibition
Monoamine oxidases (MAOs) are flavoproteins which catalyze the
oxidative deamination of several neurotransmitters, such as serotonin,
noradrenaline, dopamine, tyramine, benzylamine, etc., to their corre-
sponding aldehydes, hydrogen peroxide and ammonia (Lin et al.,
2003).
In a previous work, in which the horseradish peroxidase-linked
assay was used to determine the inhibition of the oxidative deamination
of tyramine by MAO-A, we established that A. muricata AE was a good
inhibitor (IC50=19.31 µg/ml) (Grosso et al., 2015). In this study, so as
to guarantee the reproducibility of this finding, we reevaluated a new
AE and a similar result was obtained (IC50 value of 12.0 ± 0.2 µg/ml).
However, this peroxidase-linked assay is prone to false positive results
due to different reasons: compounds with a lower oxidation–reduction
potential than 4-aminoantipyrine may act as proton donors in the
peroxidase reaction; phenolic substances present in the extracts may
condense with the oxidized form of 4-aminoantipyrine to form colored
products (Schmidt et al., 2003); and phenolic compounds with high
H2O2 scavenging activity can deplete the concentration of this ROS,
decreasing the rate of the peroxidase reaction. Bearing these in mind, in
this paper the MAO-A inhibition was determined by a second method
that exploits the formation of 4-hydroxyquinoline, which resulted in a
notably higher IC50 value of 185.8 ± 46.9 µg/ml. Both IC50 values
attest that the AE is pharmacologically active. Nonetheless, it was less
active than the positive control, clorgyline (IC50=25 ng/ml).
mApoE-L-AE, mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE were
also tested to assess any loss of inhibition properties (Fig. 5). At all
tested concentrations, mApoE-PC-AE was the most active nanoformu-
lation, reaching 37.6% inhibition at 30 µg/ml, up to 45.1% at 60 µg/ml
(for the peroxidase-linked assay). Unfortunately, the highest con-
centration (100 µg/ml) of mApoE-P-AE and mApoE-PC-AE was not
tested due to solubility problems. Nevertheless, the AE and the treated
AE (extract submitted to the process of liposome formation), were al-
ways more active than the nanoformulations. The same pattern was
observed for the assay based on the kynuramine deamination, although
with a lower inhibition capacity (data not shown).
Phospholipids have been shown to affect the activity of MAO, which
has a negatively charged catalytic site. In rat brain mitochondria
treated with a high concentration of phospholipase A2, the activity of
both isoforms, mainly of MAO-B, was able to be restored with high
concentrations of the negatively charged phospholipids (phosphati-
dylserine, cardiolipin, and phosphatidylinositol), while the zwitterionic
phospholipid phosphatydilcholine only activated MAO-A.
Phosphatydilethanolamine was not active (Huang et al., 1981). In rat
liver, using the same approach, similar results were achieved. MAO-B
activity was restored by phosphatydilcholine, phosphatidylserine,
phosphatidylinositol and phosphatydilethanolamine, with phosphati-
dylserine being the most effective. High amounts of phosphatydiletha-
nolamine slightly inhibited MAO-A, whereas the other lipids increased
MAO-A activity although not to the same extent as MAO-B (Navarro-
Welch et al., 1982). These results seem to indicate that amine substrate-
phospholipid hydrophobic complexes may probably be formed in the
presence of large amounts of phospholipid and that these complexes
may be more effectively used by the mitochondrial monoamine oxi-
dases (Navarro-Welch et al., 1982). To elucidate the mechanism by
Fig. 3. Effect of the aqueous extract (AE) and nanoformulations on hCMEC-D3
cells viability at the end of 3 h. Data are presented as mean ± SEM. Samples. A
– AE; B – phytosomes functionalized with mApoE (mApoE-P-AE); C – phyto-
somes with cholesterol and functionalized with mApoE (mApoE-PC-AE); D –
liposomes functionalized with mApoE (mApoE-L-AE); E – liposomes with cho-
lesterol and functionalized with mApoE (mApoE-LC-AE); 30 – 30 µg/ml; 60 –
60 µg/ml; 100 – 100 µg/ml. Different letters mean significant differences at
p< .05.
Fig. 4. Cellular uptake and transport of phytosomes, liposomes and the aqueous
extract (AE) across hCMEC/D3 monolayers. Data are presented as
mean ± SEM. A – AE; B – phytosomes (P-AE); C – phytosomes functionalized
with mApoE (mApoE-P-AE); D – phytosomes with cholesterol (PC-AE); E –
phytosomes with cholesterol and functionalized with mApoE (mApoE-PC-AE); F
– liposomes (L-AE); G – liposomes functionalized with mApoE (mApoE-L-AE); H
– liposomes with cholesterol (LC-AE); I – liposomes with cholesterol and
functionalized with mApoE (mApoE-LC-AE). Different letters mean significant
differences at p< .05.
which negatively charged and zwitterionic phospholipids activated
MAO function, Nałęcz et al. (1980) compared the Km value of MAO in
the presence of phosphatydilcholine, phosphatydilserine, phosphaty-
dilcholine plus phosphatidic acid and phosphatydilcholine plus tride-
cylamine. The lowest Km values were obtained for phosphatydilserine
and for phosphatydilcholine plus phosphatidic acid, while the highest
was achieved in the presence of positively charged amines (phospha-
tydilcholine+ tridecylamine). In this sense, a positively charged sur-
face would repeal the positively charged natural substrate - the biogenic
amines (such as tyramine or kynuramine) - causing the concentration of
substrate close to the negative charged catalytic site to decrease. Si-
milarly, a negatively charged surface would increase the enzyme-sub-
strate affinity, by forming the above-mentioned complexes
(Reavill et al., 1978).
Based on these assumptions, it is not surprising that, in the presence
of phosphatydilcholine, the extract of A. muricata was less able to in-
hibit MAO-A, since Km can be changed. Anyway, in in vivo experiments,
the nanoformulations will fuse with cell membranes and release the
compounds, and this limitation will be discharged.
Scavenging activity against hydrogen peroxide
A significant increase in oxidative and inflammatory stress bio-
markers has been described in MDD patients, supporting the oxidative
stress etiological hypothesis. MAO enzymatic activity over the mono-
amines is a source of H2O2, which may directly disturb the brain redox
imbalance or further produce highly reactive hydroxyl radicals via
Fenton reaction (Stafford et al., 2007; Liu et al., 2008; Zhou et al.,
2014a).
The AE displayed a strong scavenging activity against H2O2. The
calculated IC50 value of 48.9 ± 2.5 µg/ml obtained for the AE is
Fig. 5. MAO-A inhibition by the aqueous extract (AE) and nanoformulations
assessed by the horseradish peroxidase-linked assay at 30 µg/ml (A) and 60 µg/
ml (B). Data are presented as mean ± SEM. A1 – treated AE; A2 – AE; B –
phytosomes functionalized with mApoE (mApoE-P-AE); C- phytosomes with
cholesterol and functionalized with mApoE (mApoE-PC-AE); D – liposomes
functionalized with mApoE (mApoE-L-AE); E – liposomes with cholesterol and
functionalized with mApoE (mApoE-LC-AE). Different letters mean significant
differences at p< .05.
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Fig. 6. H2O2 scavenging activity of the aqueous extract (AE) from A. muricata
and of the nanoformulations at 30 µg/ml (A), 60 µg/ml (B) and 100 µg/ml (C).
Data are presented as mean ± SEM. A1 – treated AE; A2 – AE; B- phytosomes
functionalized with mApoE (mApoE-P-AE); C- phytosomes with cholesterol and
functionalized with mApoE (mApoE-PC-AE); D – liposomes functionalized with
mApoE (mApoE-L-AE); E – liposomes with cholesterol and functionalized with
mApoE (mApoE-LC-AE). Different letters mean significant differences at
p< .05.
comparable to that of the reference H2O2 scavenger ascorbic acid
(51.2 ± 4.6 µg/ml), under the same experimental conditions. At the
three tested concentrations (30, 60 and 100 µg/ml), mApoE-L-AE,
mApoE-LC-AE, mApoE-P-AE and mApoE-PC-AE were more active than
the parent extract (Fig. 6). This behavior is in accordance with the re-
sults reported by Landi-Librandi et al., (2012) who observed that li-
posomal flavonoids encapsulated in soya phosphatidylcholine:choles-
terol or in soya phosphatidylcholine: cholesteryl ethyl ether kept their
scavenging activity against H2O2. A low ratio between phospholipid
and cholesterol or cholesteryl ethyl ether also favors the antioxidant
activity.
Conclusions
The AE from A. muricata leaves revealed a phenolic-rich composi-
tion potentially exploitable for its neuroprotective effects. HPLC-DAD-
ESI-MSn analyses of the AE also allow the detection of trace amounts of
the alkaloids reticuline and coclaurine but no acetogenins were de-
tected, pointing to the safety of its consumption. This work demon-
strated that phospholipid nanoformulations functionalized with mApoE
are interesting candidates to deliver antioxidants and MAO-A inhibitors
into the brain. Taking into consideration that the bioavailability of
these compounds can be enhanced, it is expected that they will interact
in a larger scale with multiple targets and pathways. The in vitro ex-
perimental limitations inherent to the vehicles’ characteristics may be
irrelevant in future in vivo assays, since the nanoformulations will re-
lease the loaded extract.
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